CXCR4 blockade induces atherosclerosis by affecting neutrophil function.

Autor: Bot I; Division of Biopharmaceutics, Leiden Academic Centre for Drug Research, Leiden University, Leiden, The Netherlands. Electronic address: i.bot@lacdr.leidenuniv.nl., Daissormont IT; Experimental Vascular Pathology Group, Cardiovascular Research Institute Maastricht, University of Maastricht, Maastricht, The Netherlands., Zernecke A; Rudolf-Virchow-Center/DFG-Research Center for Experimental Biomedicine, University of Würzburg, Würzburg, Germany., van Puijvelde GH; Division of Biopharmaceutics, Leiden Academic Centre for Drug Research, Leiden University, Leiden, The Netherlands., Kramp B; Institute for Cardiovascular Prevention, Ludwig-Maximilians-Universität München, Munich, Germany., de Jager SC; Division of Biopharmaceutics, Leiden Academic Centre for Drug Research, Leiden University, Leiden, The Netherlands., Sluimer JC; Experimental Vascular Pathology Group, Cardiovascular Research Institute Maastricht, University of Maastricht, Maastricht, The Netherlands., Manca M; Experimental Vascular Pathology Group, Cardiovascular Research Institute Maastricht, University of Maastricht, Maastricht, The Netherlands., Hérias V; Experimental Vascular Pathology Group, Cardiovascular Research Institute Maastricht, University of Maastricht, Maastricht, The Netherlands., Westra MM; Division of Biopharmaceutics, Leiden Academic Centre for Drug Research, Leiden University, Leiden, The Netherlands., Bot M; Division of Biopharmaceutics, Leiden Academic Centre for Drug Research, Leiden University, Leiden, The Netherlands., van Santbrink PJ; Division of Biopharmaceutics, Leiden Academic Centre for Drug Research, Leiden University, Leiden, The Netherlands., van Berkel TJ; Division of Biopharmaceutics, Leiden Academic Centre for Drug Research, Leiden University, Leiden, The Netherlands., Su L; Department of Microbiology & Immunology, Lineberger Comprehensive Cancer Center, Curriculum in Genetics and Molecular Biology School of Medicine, The University of North Carolina, Chapel Hill, NC 27599-7295., Skjelland M; Department of Neurology, Rikshospitalet University Hospital, University of Oslo, Norway., Gullestad L; Department of Cardiology, Rikshospitalet University Hospital, University of Oslo, Norway., Kuiper J; Division of Biopharmaceutics, Leiden Academic Centre for Drug Research, Leiden University, Leiden, The Netherlands., Halvorsen B; Department of Internal Medicine, Rikshospitalet University Hospital, University of Oslo, Norway., Aukrust P; Department of Internal Medicine, Rikshospitalet University Hospital, University of Oslo, Norway., Koenen RR; Institute for Cardiovascular Prevention, Ludwig-Maximilians-Universität München, Munich, Germany., Weber C; Institute for Cardiovascular Prevention, Ludwig-Maximilians-Universität München, Munich, Germany., Biessen EA; Division of Biopharmaceutics, Leiden Academic Centre for Drug Research, Leiden University, Leiden, The Netherlands; Experimental Vascular Pathology Group, Cardiovascular Research Institute Maastricht, University of Maastricht, Maastricht, The Netherlands.
Jazyk: angličtina
Zdroj: Journal of molecular and cellular cardiology [J Mol Cell Cardiol] 2014 Sep; Vol. 74, pp. 44-52. Date of Electronic Publication: 2014 May 08.
DOI: 10.1016/j.yjmcc.2014.04.021
Abstrakt: Aims: The SDF-1α/CXCR4 dyad was previously shown by us and others to be instrumental in intimal hyperplasia as well as early stage atherosclerosis. We here sought to investigate its impact on clinically relevant stages of atherosclerosis in mouse and man.
Methods and Results: Immunohistochemical analysis of CXCR4 expression in human atherosclerotic lesions revealed a progressive accumulation of CXCR4(+) cells during plaque progression. To address causal involvement of CXCR4 in advanced stages of atherosclerosis we reconstituted LDLr(-/-) mice with autologous bone marrow infected with lentivirus encoding SDF-1α antagonist or CXCR4 degrakine, which effects proteasomal degradation of CXCR4. Functional CXCR4 blockade led to progressive plaque expansion with disease progression, while also promoting intraplaque haemorrhage. Moreover, CXCR4 knockdown was seen to augment endothelial adhesion of neutrophils. Concordant with this finding, inhibition of CXCR4 function increased adhesive capacity and reduced apoptosis of neutrophils and resulted in hyperactivation of circulating neutrophils. Compatible with a role of the neutrophil CXCR4 in end-stage atherosclerosis, CXCR4 expression by circulating neutrophils was lowered in patients with acute cardiovascular syndromes.
Conclusion: In conclusion, CXCR4 contributes to later stages of plaque progression by perturbing neutrophil function.
(Copyright © 2014 Elsevier Ltd. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: